Wasan et al., 1998 - Google Patents
Cationic liposome–plasmid DNA complexes used for gene transfer retain a significant trapped volumeWasan et al., 1998
- Document ID
- 4586641759382920658
- Author
- Wasan E
- Fairchild A
- Bally M
- Publication year
- Publication venue
- Journal of pharmaceutical sciences
External Links
Snippet
The goal of this study is to determine whether cationic liposomes retain any trapped volume after their complexation to plasmid DNA. This serves two purposes: to further the understanding of the physical nature of liposome/plasmid DNA complexes used in gene …
- 229920003013 deoxyribonucleic acid 0 title abstract description 141
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48792—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension
- A61K47/48815—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension the form being a liposome, i.e. a bilayered vesicle, having its surface modified by covalent attachment or complexation of the pharmacologically or therapeutically active agent and/or modifying agent.
- A61K47/48823—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension the form being a liposome, i.e. a bilayered vesicle, having its surface modified by covalent attachment or complexation of the pharmacologically or therapeutically active agent and/or modifying agent. the form being a liposome which being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Maurer et al. | Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes | |
Ulrich | Biophysical aspects of using liposomes as delivery vehicles | |
EP0792142B1 (en) | Fusogenic liposomes | |
Kalepu et al. | Liposomal drug delivery system—a comprehensive review | |
JP5388395B2 (en) | Method for producing therapeutic agent encapsulated in lipid | |
US7094423B1 (en) | Methods for preparation of lipid-encapsulated therapeutic agents | |
US7329807B2 (en) | High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them | |
Wadhwa et al. | Nanovesicles for nanomedicine: theory and practices | |
US7005140B2 (en) | Lipid particles having asymmetric lipid coating and method of preparing same | |
US6673364B1 (en) | Liposome having an exchangeable component | |
Palmer et al. | Transfection properties of stabilized plasmid–lipid particles containing cationic PEG lipids | |
Zhigaltsev et al. | Morphological behavior of liposomes and lipid nanoparticles | |
Wasan et al. | Cationic liposome–plasmid DNA complexes used for gene transfer retain a significant trapped volume | |
Trementozzi et al. | Liposome-mediated chemotherapeutic delivery is synergistically enhanced by ternary lipid compositions and cationic lipids | |
AU652552B2 (en) | Interdigitation-fusion liposomes and gels | |
Wasankar et al. | Liposome as a drug delivery system-a review | |
Odette et al. | Formation of Oxidation-and Acid-Sensitive Assemblies from Sterols and a Quaternary Ammonium Ferrocene Derivative: Quatsome-and Onion-like Vesicles and Extended Nanoribbons | |
AU646520B2 (en) | Phospholipid analogue vesicle with a succinimidyl moiety | |
Kaushal et al. | A COMPREHENSIVE REVIEW: LIPOSOMAL DRUG DELIVERY SYSTEM | |
THIRUMAL et al. | Liposomal carriers: Development, evaluation, applications with its regulatory aspects | |
Mady | Serum stability of non-cationic liposomes used for DNA delivery | |
Wasan | Biophysical characterization of catonic liposome/plasmid DNA complexes for gene therapy | |
Mady | The influence of DOPC on the permeability of lipid membrane: Detergent solubilization and NMR study | |
Naaz et al. | International Journal of Modern Pharmaceutical Research | |
Shew | Characterization of liposomal drug delivery systems utilizing cell culture methods |